Fairvalue-Calculator Fairvalue-Calculator
EN DE

China Resources Boya Bio-pharmaceutical Group (300294) Fair Value & Analysis

Healthcare · CN · Market cap 8.3B CNY

Price¥15.26
Fair Value¥7.43
Upside-51.3%
Quality95/100
Evidence: High Range ¥5.34 – ¥7.98

Analysis

China Resources Boya Bio-pharmaceutical Group (300294) currently trades at ¥15.26, while our model-based Fair Value estimate is ¥7.43 — implying the stock looks roughly 51.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.